Early experience with the FDA's Breakthrough Devices program

被引：24

作者：

Johnston, James L. ^{[1
]}

Dhruva, Sanket S. ^{[2
,3
]}

Ross, Joseph S. ^{[4
,5
,6
]}

Rathi, Vinay K. ^{[7
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

[2] San Francisco VA Med Ctr, San Francisco, CA USA

[3] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA

[4] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat CORE, 20 York St, New Haven, CT 06504 USA

[5] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA

[6] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06510 USA

[7] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA

来源：

NATURE BIOTECHNOLOGY | 2020年 / 38卷 / 08期

基金：

美国国家卫生研究院;

关键词：

PREMARKET APPROVAL; MEDICAL DEVICES; UNITED-STATES;

D O I：

10.1038/s41587-020-0636-7

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：933 / 938

页数：6

共 23 条

[1] Biomarkers in COPD
Agusti, Alvar
Sin, Don D.
[J]. CLINICS IN CHEST MEDICINE, 2014, 35 (01) : 131 - +
[2] [Anonymous], 2016, Investment Company Reporting Modernization, Securities Act Release No. 10231, Exchange Act Release No. 79095, Investment Company Act Release No. 32314, 81Fed.Reg.81870,81873
[3] Centers for Medicare & Medicaid Services, 2018, DEC MEM NEXT GEN SEQ
[4] Centers for Medicare & Medicaid Services, 2019, FY 2020 IPPS LTCH PP
[5] Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices
Dhruva, Sanket S.
Bero, Lisa A.
Redberg, Rita F.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (24): : 2679 - 2685
[6] Coverage With Evidence Development What to Consider
Foster, Norman L.
Mottola, Caren
Hoffman, John M.
[J]. JAMA NEUROLOGY, 2014, 71 (04) : 399 - 400
[7] Clinical Perspective-Early Feasibility Device Medical Studies in the United States Time for More Than Regulatory Reform
Holmes, David R., Jr.
Shuren, Jeff
Califf, Robert
Zuckerman, Bram
Abel, Dorothy
Farb, Andrew
Leon, Martin
Mack, Michael
[J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (06) : 626 - 628
[8] The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016
Hwang, Thomas J.
Darrow, Jonathan J.
Kesselheim, Aaron S.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (21): : 2137 - 2138
[9] Evaluation of technologies approved for supplemental payments in the United States
Judson, Timothy J.
Dhruva, Sanket S.
Redberg, Rita F.
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2019, 365
[10] Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation
Kesselheim, Aaron S.
Woloshin, Steven
Eddings, Wesley
Franklin, Jessica M.
Ross, Kathryn M.
Schwartz, Lisa M.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (14): : 1516 - 1518

← 1 2 3 →